The nascent psychedelics industry is taking a different path to market than the marijuana sector, despite their shared medicinal roots.
While most states moved to regulate commercial medical marijuana programs without an extensive library of research, psychedelics advocates are adopting a different strategy.
ADVERTISEMENT
“In the U.S., cannabis went for legalization in states before (there was) a ton of research,” explained Dr. Lynn Marie Morski, a former physician with the U.S. Department of Veterans Affairs who now serves as president of the Psychedelic Medicine Association.
“It led with the legalization, whereas psychedelics led with the research,” added Morski, who will speak about emerging research on the medical applications of psychedelics at The Emerald Conference, April 1-3 in San Diego.
Follow the research
Though scientists
Read full article on Marijuana Business Daily
